

## Special Issue

# Multiple Myeloma: Recent Advances in Diagnosis, Analysis and Therapeutic Management

### Message from the Guest Editor

Many studies have demonstrated multiple myeloma (MM) to be a complex and heterogeneous disease, with an expansion of genetic events that impact the prognosis of patients. Currently, next-generation sequencing allows for the understanding and classification of the genomic landscape of MM, in which the presence of “high-risk” features keeps predicting poorer outcomes, regardless of the effectiveness of novel treatments. Thus, multiple myeloma is still considered incurable, although recent clinical trials have shown promising results in regard to the stabilization of the disease, furthering the five-year threshold. However, there still remain many features requiring consideration, with the rise in improved disease monitorization through the use of the minimal residual disease analysis and its association with relapse probability. Inviting contributions: This Special Issue welcomes research articles and review papers focused on a wide scope of multiple myeloma, from basic pathology to preclinical and clinical studies.

---

### Guest Editor

Dr. Juan Manuel Rosa-Rosa  
Instituto de Investigación Sanitaria Hospital 12 de Octubre, Madrid,  
Spain

---

### Deadline for manuscript submissions

closed (20 February 2025)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/141921](https://mdpi.com/si/141921)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)